IP Library › Granted Patent US 12,440,443
Granted Patent B2
US 12,440,443 · App. 18/163,041 · Granted Oct 14, 2025

Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver

Inventors: Leo A. Kim (Brookline, MA); Joseph F. Arboleda-Velasquez (Newton, MA)
Assignee: Massachusetts Eye and Ear Infirmary
A61K9/1075A61K31/5513A61K47/10A61K47/14A61K47/24A61K9/0048A61K9/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,443
App. No.
18/163,041
Granted
Oct 14, 2025
Kind
B2
Abstract

The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBFβ-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.

Claims (26)

1. A method for treating an ocular disease or condition in a subject in need of treatment for an ocular trauma or retinal detachment, the method comprising

topically administering, to an ocular tissue of the subject, a composition in the form of a nano-emulsion comprising a core binding factor β (CBFβ)-Runt Related Transcription Factor 1 (RUNX1) inhibitor,

wherein the ocular disease or condition is associated with aberrant ocular angiogenesis or comprises a proliferative ocular condition.

2. The method of claim 1 , wherein the nano-emulsion comprises from about 3 mM to about 10 mM of the CBFβ-RUNX1 inhibitor.

3. The method of claim 1 , wherein the CBFβ-RUNX1 inhibitor comprises Ro5-3335.

4. The method of claim 1 , wherein the CBFβ-RUNX1 inhibitor binds to RUNX1 and/or CBFβ.

5. The method of claim 1 , wherein the CBFβ-RUNX1 inhibitor comprises Ro24-7429.

6. The method of claim 1 , wherein the composition comprises:

(i) from about 1% to about 3% (v/v) of an oil phase;

(ii) a surfactant;

(iii) a water phase; and

(iii) from about 0.01 mM to about 10 mM of said CBFβ-RUNX1 inhibitor dispersed within the oil phase.

7. The method of claim 6 , wherein the oil phase comprises isopropyl myristate.

8. The method of claim 6 , wherein the surfactant is propylene glycol, polyethylene glycol, or lecithin.

9. The method of claim 6 , wherein the surfactant is lecithin.

10. The method of claim 6 , wherein the water phase comprises phosphate buffered saline.

11. The method of claim 1 , wherein the average particle size of the nano-emulsion is about 200 nm or less than 200 nm.

12. The method of claim 1 , wherein the subject has ocular trauma.

13. The method of claim 1 , wherein the subject has retinal detachment.

14. The method of claim 1 , wherein the ocular disease or condition is proliferative vitreoretinopathy.

15. The method of claim 1 , wherein the composition is administered prior to surgical repair of the ocular trauma or retinal detachment.

16. The method of claim 15 , wherein the CBFβ-RUNX1 inhibitor comprises Ro24-7429.

17. The method of claim 1 , wherein the composition is administered during surgical repair of the ocular trauma or retinal detachment.

18. The method of claim 17 , wherein the CBFβ-RUNX1 inhibitor comprises Ro24-7429.

19. The method of claim 1 , wherein the composition is administered after surgical repair of the ocular trauma or retinal detachment.

20. The method of claim 19 , wherein the CBFβ-RUNX1 inhibitor comprises Ro24-7429.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2025
From: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
To: MASSACHUSETTS EYE AND EAR INFIRMARY
Reel/Frame 071027/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2023
From: KIM, LEO A.; ARBOLEDA-VELASQUEZ, JOSEPH F.
To: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
Reel/Frame 063117/0325 →
Continuity (3)
Continuation 16763932
Provisional Application 62586027 · Nov 14, 2017
Related Publication 20230277454A1 · Sep 7, 2023
References Cited (43)
US 3405122A · Berger et al. · 1968 [cited by applicant]
US 4652441A · Okada et al. · 1987 [cited by applicant]
US 4675189A · Kent et al. · 1987 [cited by applicant]
US 5019400A · Gombotz et al. · 1991 [cited by applicant]
US 5036101A · Hsu et al. · 1991 [cited by applicant]
US 5041438A · Hsu · 1991 [cited by applicant]
US 5141735A · Bellemin et al. · 1992 [cited by applicant]
US 5152923A · Weder · 1992 [cited by examiner]
US 5164376A · Hsu et al. · 1992 [cited by applicant]
US 5641773A · Pardee et al. · 1997 [cited by applicant]
US 6630477B1 · Deluge · 2003 [cited by applicant]
US 6709650B1 · Sutton et al. · 2004 [cited by applicant]
US 20120039978A1 · Moscona et al. · 2012 [cited by applicant]
US 20140004082A1 · Liu et al. · 2014 [cited by applicant]
US 20140275263A1 · Wassel et al. · 2014 [cited by applicant]
US 20160101050A1 · Lee et al. · 2016 [cited by applicant]
US 20160208246A1 · Groner et al. · 2016 [cited by applicant]
US 20190350961A1 · Arboleda-Velasquez et al. · 2019 [cited by applicant]
US 20200102384A1 · Arboleda-Velasquez et al. · 2020 [cited by applicant]
US 20200103419A1 · Arboleda-Velasquez et al. · 2020 [cited by applicant]
US 20200377888A1 · Kim et al. · 2020 [cited by applicant]
US 20230190764A1 · Arboleda-Velasquez et al. · 2023 [cited by applicant]
US 20230190959A1 · Arboleda-Velasquez · 2023 [cited by applicant]
US 20230310446A1 · Kim et al. · 2023 [cited by applicant]
[No Author Listed], “Final Report on the Safety Assessment of Myristyl Myristate and Isopropyl Myristate,” Journal of the American College of Toxicology, Jul. 1982, 1(4):55-80. [cited by applicant]
Cunningham et al., “Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction,” Proc Natl Acad Sci USA, 2012, 109(36):14592-1459… [cited by applicant]
Elsevier's Encyclopedia of Food and Health, 1st ed., Caballero (ed.), Aug. 2015, pp. 498-502. [cited by applicant]
Elsevier's Food Enrichment with Omega-3 Fatty Acids, 1st ed., Jacobsen (ed.), Jul. 2013, Chapter 5, 44 pages. [cited by applicant]
Elsevier's Modifying Lipids for Use in Food, 1st ed., Gunstone (ed.), Sep. 2006, Chapter 16, 36 pages. [cited by applicant]
Elsevier's xPharm: The Comprehensive Pharmacology Reference, 1st ed., Enna (ed.), Jan. 2007, 3 pages. [cited by applicant]
Head et al., “Ocular pathology of uncommon hematologic malignancies: a case series,” Journal of Medical Case Reports, Nov. 2007, 1:158, 4 pages. [cited by applicant]
Hedge et al., “Microemulsion: New Insights into the Ocular Drug Delivery,” ISRN Pharmaceutics, Jun. 2013, 2013:1-11. [cited by applicant]
Illendula et al., “Small Molecule Inhibitor of CBFB-RUNX Binding for RUNX Transcription Factor Driven Cancers,” EBioMedicine, Nov. 2017, 8:117-131. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2018/061156, dated May 28, 2020, 7 pages. [cited by applicant]
International Search Report for International Patent Application No. PCT/US2018/061156, mailed Mar. 14, 2019, 3 pages. [cited by applicant]
Kale et al., “Emulsion Micro Emulsion and Nano Emulsion: A Review,” Systematic Reviews in Pharmacy, Nov. 2016, 8(1):39-47. [cited by applicant]
Mishra et al., “Nanoemulsion: A Novel Drug Delivery Tool,” International Journal of Pharma Research & Review, Jul. 2014, 3(7):32-43. [cited by applicant]
Okur et al., “Novel Ocular Drug Delivery Systems: An Update on Microemulsions,” Journal of Ocular Pharmacology and Therapeutics, Jul. 2020, 36(6):342-354. [cited by applicant]
Syed et al., “Novel Treatments for Corneal Angiogenesis,” Int Ophthalmol Clin., 2017, 57(4):31-38. [cited by applicant]
Wikipedia.org [online], “Lecithin,” Nov. 1, 2017, retrieved on Feb. 27, 2019, retrieved from URL<https://en.wikipedia.org/w/index.php?title=Lecithin&oldid=808162031>, 7 pages. [cited by applicant]
Witvrouw et al., “Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335,” Antimicrobial Agents and Chemotherapy, Dec. 1992, 36(12): 2628-2633. [cited by applicant]
Wong et al., “Orbital Angiogenesis and Lymphangiogenesis in Thyroid Eye Disease: An Analysis of Vascular Growth Factors with Clinical Correlation,” Ophthalmology, 2016, 123(9):2028-2036. [cited by applicant]
Written Opinion of the International Searching Authority for International Patent Application No. PCT/US2018/061156, mailed Mar. 14, 2019, 5 pages. [cited by applicant]